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Abstract 
Background: X‑ray computed tomography (CT) imaging can be used to reveal the three‑dimensional structure of 
deep tissue with high spatial resolution. However, it cannot reveal molecular or cellular changes, and has great limita‑
tions in terms of specificity and sensitivity. Fluorescence imaging technology is one of the main methods used for the 
study of molecular events in vivo and has important applications in life science research. Therefore, the combination 
of CT and fluorescence imaging is an ideal dual‑modal molecular imaging method, which can provide data on both 
molecular function and tissue structure, and has important research value. In a previous study, Bi2S3 nanoparticles 
were wrapped with quantum dots in SiO2 to generate CT and fluorescence imaging. However, this type of probe led 
to low survival and caused innegligible in vivo toxicity in mice. Therefore, it is necessary to develop new multifunc‑
tional probes that demonstrate biocompatibility and safety in vivo.
Methods: A polyethylene glycol‑phospholipid bilayer structure was used to synthesize hybrid clusters contain‑
ing hydrophobic Bi2S3 nanoparticles and quantum dots for combined CT/fluorescence imaging. Mean particle size, 
polydispersity index, and zeta potential were used to study the stability over an 8‑week test period. In vivo CT and 
fluorescence imaging experiments were performed, and the in vivo safety of the probe was evaluated, using histo‑
pathological, biochemical, and blood analyses.
Results: The probe distinctly enhanced the CT contrast and had fluorescence imaging capability. In addition, the 
nanocomposite hybrid clusters showed a longer circulation time (>4 h) than iobitridol. The results also showed that 
the Bi2S3‑QD@DSPE probe had good biocompatibility and safety, and did not affect normal organ functioning.
Conclusions: Bi2S3‑QD@DSPE hybrid clusters exhibited remarkable performance in CT angiography and fluores‑
cence imaging in vivo.
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Background
X-ray computed tomography (CT) imaging, a traditional 
medical imaging technique, yields images with high 
spatial resolution. It can be used to determine the three-
dimensional structure of deep tissue, and to show general 
morphological characteristics of tissues. It can also pro-
vide information on some functional and metabolic fea-
tures, and has broad applications in life science research 
and clinical medicine [1–5]. However, it cannot reveal 
molecular and cellular changes characteristic of biologi-
cal activity, and has great limitations in terms of specific-
ity and sensitivity.
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Fluorescence imaging technology is one of the main 
methods used in the study of molecular events in  vivo 
and has important applications in life science research. 
Therefore, combined CT and fluorescence imaging is 
an ideal dual-modal molecular imaging technique [6, 
7], which provides unified molecular functional and tis-
sue structure imaging, and has important research value 
[8–10].
In recent years, researchers have used various metal-
lic materials to develop CT imaging probes. Rabin 
et  al. prepared polyvinyl pyrrolidone (PVP)-coated 
Bi2S3 particles which had quasi-rectangular plate-
let shape in water [5]. The Bi2S3-PVP particles had a 
high X-ray absorption efficiency and a long circulation 
time in  vivo (>2  h). Chen et  al. used a hot injection 
method to synthesize FePt nanoparticles (FePt NPs), 
which were effective for CT/MRI dual-mode imaging 
[11]. Hyeon et  al. developed tantalum oxide nanopar-
ticles (TaOx) and Rhodamine B using an in situ sol–gel 
reaction and used them for CT and fluorescence imag-
ing of a rat lymph node [6]. Of these [4–11], bismuth 
(Bi) appears to be the most promising contrast agent, 
due to its large atomic number (I, 53; Ta, 73; Pt, 78; 
Bi, 83) and X-ray attenuation coefficient (I, 1.94; Ta, 
4.30; Pt, 4.99; Bi, 5.74  cm2 g−1 at 100  keV). However, 
some problems remain to be solved; for example, it is 
difficult to control the size of Bi2S3 nanoparticles, and 
their surface is also difficult to modify, thus hindering 
their application as CT-based multifunctional probes. 
It is for this reason that use of a Bi contrast agent with 
an optical probe has seldom been reported. However, 
a variety of fluorescent materials have been used in 
fluorescence imaging, for example, fluorescent dyes 
and quantum dots (QDs). Compared with fluores-
cent dyes, which have obvious disadvantages in direct 
biological imaging, QDs show higher brightness and 
photo-stability, broad excitation profiles, narrow/sym-
metric emission spectra, and high quantum yields, and 
are therefore suited for use in many areas of biomedi-
cal imaging research.
In a previous study [12], we wrapped Bi2S3 nanoparti-
cles with quantum dots in SiO2. These composite nano-
particles showed promise for use in CT and fluorescence 
imaging in vitro and in vivo; however, they also showed 
in  vivo toxicity for mice and led to a low survival rate. 
1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (PEG-DSPE) has 
been used by some groups to prepare in vivo probes. For 
example, Sailor et al. used PEG-phospholipid to prepare 
hybrid nanoparticles that contained magnetic iron oxide 
nanoparticles, QDs, and the anticancer drug doxorubicin 
for simultaneous targeted drug delivery and dual-mode 
near-infrared fluorescence imaging and MRI of diseased 
tissue in vitro and in vivo [13]. Lu et al. used PEG 2000-
DSPE to coat Yb-based nanoparticles as a high-perfor-
mance CT contrast agent for in  vivo angiography and 
bimodal image-guided lymph node mapping, and they 
found that the gradual enhancement of signals for the 
liver and spleen continued for >2  h [14]. In the present 
study, PEG 2000-DSPE was used to synthesize hybrid 
clusters containing hydrophobic Bi2S3 nanoparticles and 
quantum dots for combined CT/fluorescence imaging 
(Fig. 1). For CT imaging of the liver and spleen, the parti-
cles produced a clear contrast enhancement after 30 min, 
Fig. 1 Schematic illustration of the procedures used for synthesis of Bi2S3‑QD@DSPE hybrid nanoprobes
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and the enhancement continued for >4  h; for fluores-
cence imaging, the liver and kidneys continued to show 
fluorescence after 24  h, indicating that the probes have 
a long circulation time. The results also showed that the 
Bi2S3-QD@DSPE probes show good biocompatibility and 
safety, and did not affect normal organ functioning. Thus, 
our results show that Bi2S3-QD@DSPE hybrid clusters 
exhibit remarkable performance in CT angiography and 
fluorescence imaging in vivo.
Results and discussion
To synthesize Bi2S3-QD@DSPE, we first prepared 
hydrophobic Bi2S3 nanoparticles and QDs. The photo-
luminescence (PL) spectra of the QDs showed that they 
had an emission wavelength of approximately 650  nm 
(Fig.  2a) with a full-width-at-half-maximum (FWHM) 
of 28 nm. TEM images showed that these hybrid clus-
ters were 30–40  nm in diameter (Fig.  2b), which was 
in good agreement with the average diameters deter-
mined by dynamic light scattering measurements 
(Fig.  3a). After the synthesis of Bi2S3-QD@DSPE, the 
stability of hybrid clusters was evaluated by examining 
changes in the mean particle size, polydispersity index 
(PDI), and zeta potential during storage at 4, 25, and 
37  °C. Figure 3 illustrates that the mean size, PDI, and 
zeta potential of the probes were approximately 50 nm, 
0.188, and −35.7  mV, respectively, and the probes did 
not show any significant changes in particle size, PDI, 
or zeta potential when maintained at 4, 25, and 37 °C for 
the 8-week test period, indicating that the probes show 
sufficient stability. The probes showed a negative zeta 
potential due to dissociation of the phosphate group in 
the PEG-phospholipid moiety, consistent with previous 
reports [15, 16].
Various concentrations of Bi2S3-QD@DSPE were dis-
persed in deionized water. As the concentration of Bi2S3-
QD@DSPE increased, the Hounsfield unit (HU) values 
obtained using the in-house-built CT system increased 
linearly (Fig. 4a, b). The probes showed higher HU values 
and CT contrast effects than the same concentration of 
iopromide.
To study their biodistribution, Bi2S3-QD@DSPE parti-
cles were injected into the tail veins of mice. Distribution 
of the probes was tracked by X-ray CT imaging before 
injection and at 30 min, 1, 2, 4, and 24 h after injection. 
Figure 5a shows that CT contrast of the heart (red arrow) 
was enhanced after 30  min and decreased 1  h after 
administration of Bi2S3-QD@DSPE, likely because the 
probes spread to the heart and then to other organs with 
blood circulation. Serial CT sectional and coronal views 
(Fig.  5b–d) revealed that the liver (orange arrow) and 
spleen (yellow arrow) showed clear contrast enhance-
ment after 30  min, and that the enhancement contin-
ued for >4  h, indicating that the probes show a long 
circulation time. However, contrast was weak after 24 h, 
which may imply that most of the probes were eventu-
ally metabolized and did not accumulate in  vivo. Fur-
thermore, the HU values of organs at several time points 
were tested (Table 1). After injection, the HU value of the 
heart began to peak at approximately 30 min, and spleen 
and liver signal intensity increased until they peaked at 
1–2 h (spleen: 107.9–513.4; liver: 123.1–257.1). The con-
trast effect in all of the examined organs returned to nor-
mal levels after 24 h, as shown in the serial CT images.
Fig. 2 UV‑vis absorption spectra and fluorescence spectra of QD (a) and TEM image of Bi2S3‑QD@DSPE hybrid clusters (b)
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The excitation wavelength of our in house-built imag-
ing system for Bi2S3-QD@DSPE was 500 nm and showed 
limited optical imaging capability in  vivo, and therefore 
the mice were sacrificed after CT imaging. In this study, 
the auto-fluorescence signal has been deducted from all 
of the results for fluorescence imaging. Distribution of 
the probes was tracked by fluorescence imaging at 1, 2, 4, 
and 24 h after injection. Figures 6 and 7 show that probes 
were enriched in the liver, spleen, and kidneys at 1 h after 
injection; the enrichment lasted for 4  h, in agreement 
with the results of CT imaging. In the spleen, fluores-
cence intensity began to peak at 1–2 h, which may imply 
that a large number of macrophages initiated phagocy-
tosis after the injection, that most probes were metabo-
lized at approximately 2  h, and had not accumulated in 
the spleen 24 h after injection; this may explain why no 
spleen uptake was observed at 24 h post-injection in the 
optical images. Interestingly, fluorescence imaging of 
the kidney and liver disagreed with CT imaging of these 
organs at 24 h, possibly because the sensitivity of the CT 
imaging system is lower than that of the fluorescence 
imaging system, and it was difficult to detect the small 
amount of probes remaining. These results indicate that 
hybrid Bi2S3-QD@DSPE nanoprobes have both CT and 
fluorescence imaging capability in vivo.
To determine whether Bi2S3-QD@DSPE caused any 
harmful effects or disease, the long-term toxicity of 
the probes was investigated by monitoring histological 
changes in several susceptible organs including the heart, 
lung, spleen, kidney, and liver for more than 2  weeks. 
Mice were dissected at 1, 3, 7, and 15 days after the injec-
tion of a single dose (0.6 mg Bi/g body weight) of Bi2S3-
QD@DSPE. Hematoxylin and eosin (H&E) staining of 
organs showed no significant evidence of tissue dam-
age or adverse effects of the nanoparticles on the organs 
(Fig. 8). We also measured serum levels of alanine ami-
notransferase (ALT) and aspartate aminotransferase 
(AST) over time to determine the effect on liver function. 
Figure 9 showed that the ALT and AST levels increased 
transiently after the injection and declined rapidly until 
they returned to normal. Jain et  al. used magnetic nan-
oparticles in rats and showed similar results [17]. Thus, 
our probes exhibit little toxicity in the liver. Given that 
blood can reflect the condition of tissues and organs, we 
performed blood analysis on mice that received either a 
single intravenous injection of 150 µL phosphate buffered 
saline (PBS) (control) or Bi2S3-QD@DSPE (0.6  mg/g) at 
the indicated time. Neither group showed significant dif-
ferences in any of the following four indexes: white blood 
cell count (WBC), red blood cell count (RBC), hemo-
globin (HGB), or platelet count (PLT), and all indexes 
were in the reference range (Table 2) [18]. These results 
further confirmed that Bi2S3-QD@DSPE nanoprobes 
Fig. 3 Physical stability of Bi2S3‑QD@DSPE during storage at 4, 25, 
and 37 °C. Changes in mean particle size (a), polydispersity index (b) 
and zeta potential (c) of Bi2S3‑QD@DSPE were examined
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Fig. 4 Phantom images of Bi2S3‑QD@DSPE hybrid clusters as a function of concentration, using X‑ray CT imaging (a) and HU measurements (b)
Fig. 5 In vivo X‑ray CT imaging. Serial CT sections (a, b) and coronal views (c, d) of a mouse at different time points after injection of Bi2S3‑QD@
DSPE hybrid clusters in solution (0.6 mg Bi/g body weight) into the tail vein [heart (a, red arrow), liver (orange arrow), spleen (yellow arrow), and 
kidney (b, green arrow)]
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had no significant effect on organs, tissues, or blood, and 
showed remarkable biocompatibility and promise as a 
contrast agent.
Conclusion
In summary, composite core–shell nanoparticles con-
taining Bi2S3 nanoparticles and QDs within a single PEG-
modified phospholipid were prepared. These nanoprobes 
exhibit effective dual-mode imaging in  vivo, and have 
the advantages of long circulation time and low toxicity. 
However, because the excitation wavelength of our in 
house-built imaging system for the contrast agent probe 
is 500  nm, which is not conducive to noninvasive opti-
cal imaging in vivo, we intend to develop a multi-mode 
probe that can fully exploit the advantages conferred by 
the near-infrared range of QDs, in future work.
Methods
Materials
Bismuth neodecanote, oleic acid (90  %), cadmium 
oxide (99.99  %), bis(trimethylsilyl) sulfide ((TMS)2S), 
hexadecylamine (90  %), tri-n-octylphosphine oxide 
(90  %), and trioctylphosphine (97  %) were purchased 
from Aldrich. Oleyl amine (90  %) was purchased from 
Aladdin. Thioacetamide and selenium powder were 
purchased from Sinopharm. 1,2-Dipalmitoyl-sn-glycero-
3-phosphoethanol-amine-N-[methoxy(polyethylene 
glycol)-2000] (PEG-DSPE, 99  %) was purchased from 
Avanti. All chemicals were used as received, unless oth-
erwise stated.
Characterization
Nanoparticle spectra were measured using a 2550 UV–
visible spectrophotometer (Japan) and a LS-55 spectro-
photometer (USA). Elemental analysis of the resultant 
hybrid clusters was performed using an inductively cou-
pled plasma atomic emission spectrometer (Germany). 
Animal blood analysis was carried out on a SP-4430 dry 
biochemical analyzer (Japan) and a CA-700 automatic 
blood analyzer (China). TEM images were captured using 
a Tecnai G20 U-Twin transmission electron microscope 
(USA).
Synthesis of Bi2S3‑QD@DSPE
Based on previously reported methods, we prepared 
Bi2S3 nanoparticles coated with oleic acid [4]. Core–
shell CdSe/ZnS quantum dots with an emission wave-
length of 650  nm were synthesized using a previously 
described two-step method [19, 20]. After addition of 
PEG-DSPE, hydrophobic Bi2S3 and QD were modi-
fied and transformed into hydrophilic nanocomposite 
Table 1 CT values of the heart, kidney, liver and spleen of mouse before the injection (previous) and at indicated time 
intervals after the injection
Previous 30 min 1 h 2 h 4 h 24 h
Heart 81.8 196.2 123.1 81.8 91.9 102.1
Kidney 113.0 170.9 111.5 107.2 144.1 114.4
Liver 123.1 192.6 250.5 257.1 256.3 131.8
Spleen 107.9 474.3 513.4 488.1 393.9 131.1
Fig. 6 In vivo whole‑body optical imaging after injection with Bi2S3‑
QD@DSPE hybrid clusters in solution [bright‑field (left), fluorescent 
(middle), and merged (right) images]
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hybrid clusters, Bi2S3-QD@DSPE. The main steps were 
performed according to previously reported meth-
ods [13, 21]. In brief, Bi2S3 nanoparticles and QD were 
mixed with PEG-DSPE in chloroform. Bi2S3-QD@
DSPE hybrid clusters were prepared by evaporating the 
organic solvent in a rotary evaporator under vacuum 
with 300r/min rotation speed for 30 min and then flush-
ing with a N2 stream to remove any residual traces of 
organic solvent. The lipid film, deposited in the reaction 
vial, was hydrated with water and subjected to ultra-
sonication. The resulting dispersion was purified by 
centrifugation using a Millipore filter (Centrifugal Filter 
Devices, 100 K) to remove excess PEG-DSPE. The final 
nanoparticles were redispersed in PBS for use in further 
experiments.
CT imaging of Bi2S3‑QD@DSPE
Various concentrations of Bi2S3-QD@DSPE (3.14, 6.27, 
12.54, 18.81, 25.08, and 31.4  mg of Bi/mL) dispersed in 
deionized water were prepared in 1.5-mL microtubes. A 
high-resolution CT system was constructed and applied 
for imaging, using the following imaging parameters: 
spatial resolution of 100 µm, tube voltage of 50 kV, and 
tube current of 0.800 mA.
Measurement, polydispersity index (PDI), and zeta 
potential of Bi2S3‑QD@DSPE
The mean particle size, PDI, and zeta potential of Bi2S3-
QD@DSPE were measured during storage at 4, 25, and 
37  °C using a nano-ZS90 dynamic light scattering (Mal-
vern, UK) according to the manufacturer’s instructions.
In vivo CT and fluorescence imaging
Balb/C mice with an average age of 6–8  weeks were 
purchased from the Hubei Medical Laboratory Animal 
Center. All animal studies were approved by the Animal 
Experimentation Ethics Committee of Huazhong Uni-
versity of Science and Technology. Balb/C mice (male) 
was anesthetized using 2  % chloral hydrate and 10  % 
urethane. Subsequently, Bi2S3-QD@DSPE (0.6  mg Bi/g 
body weight) was injected through the tail vein into the 
mice and CT imaging was performed at appropriate time 
points (pre-injection, 30 min, 1, 2, 4, and 24 h) after tail 
vein injection. The mice were then perfused and cleared 
with PBS for fluorescence imaging. Experiments were 
performed in quintuplicate using 5 mice. A high-resolu-
tion CT system was constructed and applied for imaging, 
using the following imaging parameters: spatial resolu-
tion of 100 µm, tube voltage of 50 kV, and tube current of 
Fig. 7 In vivo optical imaging of organs after injection with Bi2S3‑QD@DSPE hybrid clusters in solution at 1, 2, 4, and 24 h (bright‑field (upper, color 
image), bright‑field (middle, black-and-white image), and fluorescent (lower) images)
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0.800 mA. Fluorescence images of Bi2S3-QD@DSPE were 
acquired using a filter set (excitation filter: 469/35  nm; 
emission filter: 655/40  nm) and calibrated using an 
auto-fluorescent background filter set (excitation filter: 
396/40 nm; emission filter: 655/40 nm). The CT and fluo-
rescence imaging systems were both built in-house [22].
In vivo safety evaluation of probes
The male Balb/C mice were randomly assigned to two 
groups, with five in each group. After receiving a single 
intravenous injection of either PBS (control) or probes, 
250-µL blood samples were collected from each mouse 
by extraction of orbital venous plexus blood, including 
200 µL of blood for liver function tests (ALT and AST 
assays, carried out on a SP-4430 dry biochemical ana-
lyzer) and 50  µL of blood for blood analysis (measured 
Fig. 8 H&E‑stained tissue sections from mice to observe the time course of the histological changes in the heart, lung, spleen, kidney, and liver tis‑
sue of mice receiving a single intravenous injection of PBS (control) or Bi2S3‑QD@DSPE hybrid clusters solution (0.6 mg Bi/g body weight)
Fig. 9 Changes in serum liver enzyme levels as a function of time 
(n = 5)
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using a CA-700 automatic blood analyzer). Organs, 
including heart, lung, spleen, kidney, and liver were 
stained with H&E at the appropriate time points (1, 3, 7, 
and 15 d) and observed under a light microscope at 10× 
magnification.
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